- Home
- PMT vs SNDX Comparison
PMT vs SNDX Comparison
Compare PMT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMT
- SNDX
- Stock Information
- Founded
- PMT 2009
- SNDX 2005
- Country
- PMT United States
- SNDX United States
- Employees
- PMT N/A
- SNDX N/A
- Industry
- PMT Real Estate Investment Trusts
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- PMT Real Estate
- SNDX Health Care
- Exchange
- PMT Nasdaq
- SNDX Nasdaq
- Market Cap
- PMT 1.1B
- SNDX 1.1B
- IPO Year
- PMT 2009
- SNDX 2016
- Fundamental
- Price
- PMT $12.75
- SNDX $10.70
- Analyst Decision
- PMT Buy
- SNDX Strong Buy
- Analyst Count
- PMT 9
- SNDX 11
- Target Price
- PMT $14.75
- SNDX $35.91
- AVG Volume (30 Days)
- PMT 998.1K
- SNDX 2.3M
- Earning Date
- PMT 04-22-2025
- SNDX 05-05-2025
- Dividend Yield
- PMT 12.58%
- SNDX N/A
- EPS Growth
- PMT N/A
- SNDX N/A
- EPS
- PMT 0.86
- SNDX N/A
- Revenue
- PMT $591,251,000.00
- SNDX $43,722,000.00
- Revenue This Year
- PMT N/A
- SNDX $263.44
- Revenue Next Year
- PMT $1.13
- SNDX $129.44
- P/E Ratio
- PMT $14.80
- SNDX N/A
- Revenue Growth
- PMT N/A
- SNDX N/A
- 52 Week Low
- PMT $11.77
- SNDX $9.66
- 52 Week High
- PMT $15.22
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- PMT 45.25
- SNDX 38.98
- Support Level
- PMT $12.59
- SNDX $9.67
- Resistance Level
- PMT $12.89
- SNDX $14.24
- Average True Range (ATR)
- PMT 0.30
- SNDX 0.93
- MACD
- PMT 0.07
- SNDX -0.26
- Stochastic Oscillator
- PMT 62.60
- SNDX 22.62
About PMT PennyMac Mortgage Investment Trust of Beneficial Interest
PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.